Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Peptides Statistics: What the Latest Research Data Reveals About Safet

Key Takeaways The latest research reveals compelling evidence about peptide therapeutics' growing impact on modern medicine, with over 80 approved drugs generating £70 billion in global sales. Over 170 peptides are in active clinical development, with the glob

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Key Takeaways

The latest research reveals compelling evidence about peptide therapeutics' growing impact on modern medicine, with over 80 approved drugs generating £70 billion in global sales.

Over 170 peptides are in active clinical development, with the global market projected to reach £335 billion by 2034 at 10.91% CAGR.

GLP-1 receptor agonists demonstrate proven efficacy with 1.8% HbA1c reduction and 6.1kg weight loss in clinical trials

Approved peptide drugs show favourable safety profiles, but unregulated products pose contamination risks, with purity ranging from 1.7% to 100%

Regulatory compliance varies significantly: the FDA classifies peptides as drugs, whilst WADA prohibits many peptides in competitive sport.

Immunogenicity remains the primary safety concern, with some peptides causing antibody formation in up to 49% of patients during trials.

The evidence supports peptides as effective therapeutics when obtained through regulated channels, but emphasises the importance of medical supervision and avoiding unregulated sources for optimal safety outcomes.

Peptides have revolutionised modern medicine, with more than 80 peptide drugs approved worldwide and generating over $70 billion in pharmaceutical sales in 2019.

More than 100 peptide drugs are currently FDA-approved in the U.S. alone, whilst 33 non-insulin peptide therapeutics have been approved globally since 2000.

What Are Peptides and Polypeptides: Simple Research Definitions

Oligopeptides contain fewer than 20 amino acids, though some sources define this category as having between two and 20 residues.

Polypeptides comprise 20 to 50 amino acids. Chains of fewer than 20 amino acids are called oligopeptides. These include dipeptides, tripeptides and tetrapeptides.

Peptides contain two or more amino acids, usually 100 or fewer.

Proteins consist of longer chains with more than 100 amino acids, though some classifications place the cutoff at 50 amino acids.

Molecular weight provides another difference: peptides possess molecular weights below 5000 Da, whilst proteins exceed this value.

This definition makes insulin the smallest protein at 5800 Da.

Current Peptide Drug Approval Statistics and Market Data

FDA-Approved Peptide Therapeutics by Year (2000-2024)

Regulatory approvals have accelerated in the last two decades. Since 2000, 33 non-insulin peptide drugs have received approval worldwide.

The FDA approved 102 therapeutic peptides for applications of all types, while over 80 peptide drugs gained global approval as of 2023.

The number of peptides entering clinical trials from 2000 to 2010 nearly doubled compared to the 1990s.

Recent approvals include 12 peptides fast-tracked through the EMA's PRIME scheme in 2024. This cut Phase 3 study durations by nine months.

The FDA granted orphan-drug status to 47 peptide candidates in 2024, up from 32 in 2023.

Global Peptide Drug Market Revenue: $70 Billion Analysis

The peptide therapeutics market demonstrates resilient financial performance. Global sales exceeded $39.71 billion in 2019.

The market was valued at $131.95 billion in 2025. Market projections forecast growth to $334.95 billion by 2034, exhibiting a CAGR of 10.91%.

Another analysis projects the market reaching $70.20 billion by 2031 at a 7.16% CAGR.

Top-Selling Peptide Medications and Their Indications

Semaglutide led global peptide drug sales in the first half of 2023 with $71.65 billion.

Eli Lilly's Trulicity (dulaglutide) generated $4.02 billion in 2020.

Novo Nordisk's semaglutide and liraglutide combined for $6.12 billion in 2020.

Clinical Trial Pipeline: 170+ Peptides in Active Development

More than 170 peptides are in active clinical development, with over 280 peptide drugs undergoing preclinical and clinical studies.

Currently, 38 peptide drugs are in phase III clinical trials.

Research Data on Peptide Efficacy Across Therapeutic Areas

GLP-1 Receptor Agonists: Type 2 Diabetes Treatment Success Rates

Semaglutide achieved a 1.8% HbA1c reduction and 6.1 kg weight loss in phase III trials.

Cardiovascular outcome studies showed substantial MACE reductions: 13% with liraglutide and 26% with semaglutide.

Network meta-analysis of 6,213 patients revealed that semaglutide 2.0mg delivered the strongest glucose-lowering effect at -1.74% HbA1c reduction and -5.51 kg weight loss.

Peptides for Muscle Growth: Evidence from Clinical Studies

Pea peptide supplementation combined with resistance exercise substantially increased muscle thickness, upper limb grip strength, and cross-sectional area of muscle fibres.

Collagen peptides with 14 weeks of resistance training produced a 70% increase in patellar tendon length and 60% increase in tendon cross-sectional area.

Anti-Ageing Peptides: Collagen and Copper Peptide Research Findings

Eight-week collagen peptide treatment resulted in 40% pain reduction and 25% functional improvement in meniscopathy patients.

Long-term supplementation (10-20 g/day for 6-9 months) showed substantial benefits, with 20 g daily improving physical component scores in females (p=0.013).

Copper peptide studies showed skin improvements of 60% to 80%.

Antimicrobial Peptides: Wound Healing and Infection Control Data

Cancer Treatment Peptides: Response Rate Statistics

DrugBank identifies 460 cancer-targeting agents, with peptide-based drugs representing 6.3% (29 agents). Twenty-eight approved anticancer peptide drugs and 80 in clinical trials, show expanding therapeutic applications.

Are Peptides Safe: Comprehensive Safety Statistics and Adverse Event Data

Safety profiles for approved peptide therapeutics differ from unregulated formulations, with immunogenicity and adverse event data revealing distinct risk patterns.

Immunogenicity Rates: Peptides vs Biologics Comparison

Antidrug antibodies can develop over time and reduce efficacy or cause adverse immune reactions. Taspoglutide development halted during Phase III trials after ADA formation occurred in 49% of subjects, with 31 of 51 patients withdrawing due to allergic or anaphylactoid reactions. FDA guidelines require immunogenicity risk assessment for impurities above 0.1%.

Common Side Effects: Incidence Rates from Clinical Trials

MHRA received 7,228 reports of gastrointestinal reactions with GLP-1RAs for weight management. This included 68 hospitalisations. FAERS analysis identified 287,201 adverse events associated with GLP-1RAs, with Ozempic showing 43.9% serious adverse events. Peptide cancer vaccines produced six vaccine-related severe adverse events in 500 patients. All were grade 3 reactions.

Long-Term Safety Monitoring Results

Clinical trials lasting 6 to 12 months may never detect ADA formation, which develops over extended use. Post-marketing surveillance depends on voluntary reporting and is designed poorly to detect gradual, cumulative effects.

Contamination Risks in Unregulated Peptide Products

CJC-1295 purity ranged from 1.7% to 100%, and TB-500 from 3.2% to 99.9% in testing. Independent testing found purity discrepancies compared to supplier claims.

Injection-Related Complications: Statistical Overview

CGRP monoclonal antibody studies reported 65,792 adverse events, with injection site pain affecting 24.37% of galcanezumab users. Galcanezumab produced 10,012 injection-site adverse events, representing 59.82% of all reported reactions.

Are Peptides Legal: Regulatory Status and Compliance Data

Regulatory frameworks governing peptides differ across jurisdictions and create complex compliance requirements for manufacturers, prescribers and consumers.

MHRA and FDA Regulatory Classifications

The FDA defines peptides as amino acid chains containing 40 or fewer amino acids and regulates them as drugs rather than biologics.

Compounding occurs under Section 503A and 503B frameworks, with 503A facilities preparing patient-specific medications pursuant to individual prescriptions.

MHRA regulations classify products making medicinal claims as medicines subject to the Human Medicines Regulations 2012.

MHRA defines medicinal products as substances that prevent or treat disease, or modify physiological function.

World Anti-Doping Authority Banned Substances List

WADA's 2026 Prohibited List has S2 peptide hormones, growth factors and related substances as prohibited at all times.

Prescription vs Over-the-Counter Peptide Statistics

About 14 of 19 peptides classified as Category 2 substances may move to Category 1 status and expand legal compounding access. Peptides meeting FDA approval criteria, possessing USP monographs, or appearing on the 503A Bulks List qualify for compounding.

Enforcement Actions Against Unauthorised Peptide Sales

Coordinated enforcement operations arrested nearly 800 suspects and dismantled 123 criminal groups. MHRA confirmed investigations into UK clinics making medicinal claims for peptide treatments. The FDA issued warning letters targeting facilities with RUO GLP-1s sold without prescriptions.

Conclusion

This piece covers their molecular definitions and market performance, along with clinical applications. We got into efficacy statistics across therapeutic areas. GLP-1 receptor agonists achieve 1.8% HbA1c reductions. Collagen peptides demonstrate 70% improvements in tendon length.

FAQs on Peptide Statistics

What exactly are peptides, and how do they differ from proteins?

Peptides are short chains of amino acids linked by peptide bonds, typically containing between 2 and 100 amino acids. The main difference from proteins lies in their length and structure: peptides generally have molecular weights below 5000 Da and often lack stable three-dimensional structures, whilst proteins contain more than 100 amino acids, exceed 5000 Da in molecular weight, and fold into complex three-dimensional conformations with multiple functional domains.

How many peptide drugs are currently approved for medical use?

More than 100 peptide drugs are currently FDA-approved in the United States, with over 80 peptide drugs approved worldwide as of 2023. Since 2000, 33 non-insulin peptide therapeutics have received global approval. Additionally, more than 170 peptides are currently in active clinical development, with 38 in phase III clinical trials.

Are peptides effective for muscle growth and recovery?

Clinical studies demonstrate that certain peptides can support muscle development when combined with resistance training. Research shows pea peptide supplementation significantly increased muscle thickness, upper limb grip strength, and muscle fibre cross-sectional area. Collagen peptides combined with 14 weeks of resistance training produced a 70% increase in patellar tendon length and 60% increase in tendon cross-sectional area.

What are the main safety concerns associated with peptide use?

The primary safety concerns include immunogenicity (development of antidrug antibodies), gastrointestinal reactions, and contamination risks in unregulated products. Clinical data show that MHRA received 7,228 reports of gastrointestinal reactions with GLP-1 receptor agonists, whilst independent testing of unregulated peptides revealed significant purity discrepancies, with some products showing purity levels as low as 1.7% compared to supplier claims.

Are peptides legal to purchase and use in the UK?

The legality depends on the specific peptide and its intended use. Peptides making medicinal claims are classified as medicines under the Human Medicines Regulations 2012 and require proper authorisation. FDA-approved peptides can be legally compounded under specific frameworks when prescribed by healthcare professionals. However, the World Anti-Doping Authority prohibits many peptides in competitive sports, and the MHRA actively investigates clinics making unauthorised medicinal claims for peptide treatments.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Research context

Read sources and limitations before applying a claim.

Peptides targeted at prostate cancer mutation according to research

Peptides developed by Michigan researchers could lead to a targeted therapy for half of all prostate cancer patients. University of Michigan researchers have identified a large molecule that selectively attacks prostate tumors that have a genetic anomaly without harming healthy cells. This mutation affects half of all prostate cancer patients. The fusion of the genes TMPRSS2 and ERG is a key step in the development of prostate cancer, but it has been difficult to target with small-molecule drugs. Gene rearrangements are deemed poor drug targets because of their location within the cell’s nucleus and absence of enzyme activity. The Michigan team tested large-molecule peptides in animal models, finding that it disrupted ERG function and curbed the growth of prostate tumors that expressed the gene fusion. The peptides did not affect cells without ERG fusion. The research is published in Cancer Cell. “This is an example of how we can deliver precision therapy for prostate cancer: Only patients who have the ERG gene fusion would be matched with this agent. But it’s useful because the ERG fusion is so prevalent,” said senior author Arul Chinnaiyan, M.D., director of the Michigan Center for Translational Pathology and a professor of pathology at Michigan. After skin cancer, prostate cancer is the most common cancer and the third-leading cause of cancer death in American men, according to the American Cancer Society.The five-year survival rate for local- and regional-stage prostate cancer is nearly 100%, but it drops dramatically to 28% for prostate cancer that has spread to distant lymph nodes, bones or other organs. But some men appear to have treatable, localized cancer, yet end up developing aggressive metastasis. University of Toronto scientists pinpointed a set of genetic mutations that could help oncologists predict a patient’s risk of their cancer spreading after treatment. Meanwhile, Tokai, which has been working on the small molecule galeterone, hit a snag last summer when the drug failed in a phase 3 trial. The company laid off more than half its staff and stopped enrollment of a galeterone trial in patients with metastatic castration-resistant prostate cancer who have become resistant to the drug Xtandi. While the large-molecule approach is promising, it has a couple of hurdles to overcome. The peptides tend to break down quickly, before they arrive at the target, while large molecules can’t pass through the cell membrane. The University of Michigan researchers sidestepped the first issue by creating protein-like chains that were mirror images of the peptides. The team plans to create a 3D outline of how the peptides bind to ERG, with the goal of developing a small molecule that blocks ERG. WarningTHE GOODS OFFERED BY THE SELLER IS INTENDED FOR SCIENTIFIC AND DEVELOPMENT PURPOSES ONLY. The goods offered by the Seller include chemical substances that shall not be used as a drug, medicine, active substance, medical aid, cosmetic product, a substance for production of a cosmetic product neither for human consumption that is any food or food supplement or otherwise similarly used on humans or animals. References / Links Rahim, S., Minas, T., Hong, S. H., Justvig, S., Celik, H., Kont, Y. S., Han, J., Chen, K., Li, Y., Kong, Y., Ma, Y., Sun, Y., Triche, T., Bieging-Rolett, K., Tuntland, T., Serkova, N., Ratan, R., O’Hare, P., & Chinnaiyan, A. M. (2014). A small molecule inhibitor of ERG for prostate cancer treatment. Cancer Cell, 26(2), 151–165. PubMed Shaikhibrahim, Z., Offermann, A., Braun, M., Menon, R., Queisser, A., Boehm, D., Nowak, M., Perner, S., & Kristiansen, G. (2012). ERG fusion protein expression and serine 21 phosphorylation in prostate cancer. The Prostate, 72(11), 1213–1221. PubMed Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X. W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., Lee, C., Montie, J. E., Shah, R. B., Pienta, K. J., Rubin, M. A., & Chinnaiyan, A. M. (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science, 310(5748), 644–648. PubMed Nguyen, H. G., & Yang, C. S. (2021). Targeting TMPRSS2-ERG fusion in prostate cancer: therapeutic implications. Frontiers in Oncology, 11, 679826. PubMed

Source: particlepeptides.com ↗

Peptides in Biomedical Research: The Future of Pharmaceuticals

First of all, it is necessary to highlight the fact that more than 7000 naturally occurring peptides have been gradually discovered since the last century. In the human body, these peptides perform many important roles as hormones, growth factors, neurotransmitters, ion channel ligands or anti-infective agents. Research peptides are simply those that are used in scientific research for the purpose of obtaining knowledge and the results of their action, especially for the development of future farmaceuticals. Interest in peptides has increased recently, especially from pharmaceutical research and development. These potent and selective signaling molecules, which bind to specific cell surface receptors in the body to trigger various intracellular effects, have been shown to be highly effective and relatively safe in therapeutic applications. They are generally very well tolerated by patients and participants in clinical trials. Their action is highly selective and effective, therefore this promising potential in the field of medical use is the driving force for new and new research, studies and experiments. The surge in demand for research peptides is therefore part of the path to the pharmaceuticals and therapeutics of the future and overall progress in the field. Research Peptides vs Medicines? The essential difference between approved medicines and research peptides is that research peptides are intended exclusively for scientific and research purposes and experiments "in vitro", which means "in glass", that is, outside the body. They are not yet approved as medicines that a doctor could prescribe to treat any disease. Hundreds of peptide therapeutics have already been investigated and evaluated in clinical trials. It is the research that many scientists around the world are doing that often uses research peptides in laboratories to study beyond traditional peptide design. The goal is to discover variants of peptides that could subsequently become pharmaceuticals. On the basis of peptides, about 60 pharmaceutical medicines have already reached the market, which have passed everything necessary for approval by the authorities. In the US, it is the Food and Drug Administration (FDA) that must approve the medicine. Examples include the prostate cancer treatment LupronTM or the type 2 diabetes treatment VictozaTM. Both of these medicines achieved large sales turnovers. Such approved drugs are not research peptides. Research peptides cannot be listed or prescribed as medicines. Although they show excellent and safe results and effects in studies, they must go through a rigorous process of clinical trials and subsequent FDA approval. They can be used for research and scientific purposes, as they could lead to very important new discoveries and the development of future drugs. However, until then, they cannot be prescribed or used for prevention by doctors. Research Peptides As a Basis For Future Medicines Due to the promising potential of peptides for medical applications, more and more intensive research, studies and experiments with peptides are needed in order to discover the pharmaceutical substances of the present and future. Therefore, the demand for research peptides is increasing intensively to support the progress in these new fields of research. In clinical studies, research peptides have demonstrated exceptional safety and tolerability by study participants, while maintaining high selectivity, efficacy, and predictable metabolism. Peptides therefore represent a huge opportunity for further therapeutic development. The large increase in obesity and type 2 diabetes, as well as cancer mortality, has made these two areas one of the main areas that drive research and development of peptide-based medicines. In North America, but not only there, metabolic diseases such as obesity and diabetes are a serious and growing problem. Similarly, the increase in deaths from oncological diseases leads to the search for alternatives to traditional chemotherapy. Both of these areas call for the development of peptide-based medicines and stimulate further research. However, peptide research has also expanded into other areas. For example, in the field of infectious diseases, inflammation or rare diseases, and it could also have potential in diagnosis and vaccination. Thus, research peptides serve as the basis for experiments and development in laboratories. Crucial research and studies take place there, focusing mainly on uncovering and proving the therapeutic potential of peptides for future medicines. They are therefore extremely important for the further development and possible effective future medicines that could be used in the treatment of serious diseases. WarningTHE GOODS OFFERED BY THE SELLER IS INTENDED FOR SCIENTIFIC AND DEVELOPMENT PURPOSES ONLY. The goods offered by the Seller include chemical substances that shall not be used as a drug, medicine, active substance, medical aid, cosmetic product, a substance for production of a cosmetic product neither for human consumption that is any food or food supplement or otherwise similarly used on humans or animals. References / Links Fosgerau, K., & Hoffmann, T. (2015). Peptide therapeutics: current status and future directions. Drug Discovery Today, 20(1), 122–128.DOI Otvos, L., & Wade, J. D. (2014). Current challenges in peptide-based drug discovery. Frontiers in Chemistry, 2, 62.DOI Muttenthaler, M., King, G. F., Adams, D. J., & Alewood, P. F. (2021). Trends in peptide drug discovery.Nature Reviews Drug Discovery, 20, 309–325. DOI Lau, J. L., & Dunn, M. K. (2018). Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorganic & Medicinal Chemistry, 26(10), 2700–2707.DOI FDA – Drugs@FDA Database - https://www.accessdata.fda.gov/scripts/cder/daf/ Craik, D. J., Fairlie, D. P., Liras, S., & Price, D. (2013).The future of peptide-based drugs. Chemical Biology & Drug Design, 81(1), 136–147. DOI

Source: particlepeptides.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides